India trying to save vaccines by delaying shots for Covid patients: Government panel

India is trying to save scarce Covid-19 vaccines by delaying shots for those who have recovered from the disease, the head of a government panel said, adding the campaign should not have been opened to all adults before covering the most vulnerable.

Under fire for his handling of the world’s worst rise in coronavirus infections, Prime Minister Narendra Modi made all adults eligible for vaccination from May 1.

Vaccine shortages have now forced many regions, including the capital New Delhi, to again prioritise those aged above 45.

The federal government on Wednesday said patients should go for their vaccination three months after recovery, compared with the earlier recommendation of about one month. It did not give a reason.

“It’s been done to save vaccine doses,” Narendra Kumar Arora, head of the government’s National Technical Advisory Group on Immunisation, told Reuters on Friday. “We discussed delaying it by three months, six months or nine months, but finally we said ‘we can manage it with three months, let’s do three months for now'”.

Arora said that given the vaccine shortage in India, the focus should have been on immunising the most at risk.

“Our group prioritised those aged 45 or more,” he said. “Because 75% of the mortality and morbidity is in that age group.”

The Ministry of Health and Family Welfare said on April 19 that the decision to include all adults in the immunisation campaign was taken in a meeting chaired by Modi.

The ministry and Modi’s office did not respond to a request for comment.

India has administered about 192 million doses, the most after China and the United States, but given the necessary two doses to only about 3% of its 1.35 billion people.

  • Related Posts

    • Pharma
    • December 23, 2024
    • 45 views
    Healthcare, pharma sectors raise Rs 14,811 crore via IPOs in 2024

    India’s healthcare and pharmaceutical sectors raised Rs 14,811 crore through initial public offerings (IPOs) in 2024, the largest since 2019, driven by strong domestic demand amid expanding global opportunities. According…

    • Pharma
    • December 23, 2024
    • 53 views
    NPPA sets retail prices for 65 drugs, revises ceiling for 20 formulations

    The National Pharmaceutical Pricing Authority (NPPA) has fixed retail prices for 65 new drug formulations and notified ceiling price fixation of 13 formulations. The regulatory body, under the Department of…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Healthcare, pharma sectors raise Rs 14,811 crore via IPOs in 2024

    Healthcare, pharma sectors raise Rs 14,811 crore via IPOs in 2024

    NPPA sets retail prices for 65 drugs, revises ceiling for 20 formulations

    NPPA sets retail prices for 65 drugs, revises ceiling for 20 formulations

    India-Latin America trade and collaboration prospects discussed at Kerala University conference

    India-Latin America trade and collaboration prospects discussed at Kerala University conference

    Karnataka Govt Files Criminal Cases Against Pharma Firm In Ballari Maternal Deaths Case

    Karnataka Govt Files Criminal Cases Against Pharma Firm In Ballari Maternal Deaths Case

    NPPA Notifies Ceiling Price Of 13 Formulations, Retail Price Of 65 New Drugs

    NPPA Notifies Ceiling Price Of 13 Formulations, Retail Price Of 65 New Drugs

    Over 14,000 PMBJK Centres Set Up To Provide Generic Medicines: Govt

    Over 14,000 PMBJK Centres Set Up To Provide Generic Medicines: Govt